WO2002053172A3 - Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover - Google Patents
Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover Download PDFInfo
- Publication number
- WO2002053172A3 WO2002053172A3 PCT/US2001/049272 US0149272W WO02053172A3 WO 2002053172 A3 WO2002053172 A3 WO 2002053172A3 US 0149272 W US0149272 W US 0149272W WO 02053172 A3 WO02053172 A3 WO 02053172A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- wounds
- rate
- peptide substrate
- turnover
- matrix
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002241664A AU2002241664A1 (en) | 2000-12-29 | 2001-12-21 | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75307800A | 2000-12-29 | 2000-12-29 | |
US09/753,078 | 2000-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002053172A2 WO2002053172A2 (en) | 2002-07-11 |
WO2002053172A3 true WO2002053172A3 (en) | 2004-02-26 |
Family
ID=25029062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/049272 WO2002053172A2 (en) | 2000-12-29 | 2001-12-21 | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002241664A1 (en) |
WO (1) | WO2002053172A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003299187A1 (en) * | 2002-10-01 | 2004-04-23 | Johnson And Johnson Medical Limited | Controlled release therapeutic wound dressings |
DE102005007468A1 (en) * | 2005-02-16 | 2006-08-31 | Beiersdorf Ag | Covalently bound active complexes, from which stress-activatable skin enzymes release an active substance |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2131813A (en) * | 1982-12-16 | 1984-06-27 | Monsanto Co | Peptide substrates for mammalian collagenase |
EP0126009A1 (en) * | 1983-05-16 | 1984-11-21 | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | Peptide derivatives, their preparation and use as elastase inhibitors |
US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US5612194A (en) * | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
US5618790A (en) * | 1990-10-05 | 1997-04-08 | Queen's University At Kingston | Protease mediated drug delivery system |
WO2000063233A2 (en) * | 1999-04-21 | 2000-10-26 | University Of Florida Research Foundation, Inc. | Peptides and the use thereof to control pests |
WO2001046220A2 (en) * | 1999-12-22 | 2001-06-28 | Polymun Scientific Immunbiologische Forschung Gmbh | Bioactive oligopeptides |
WO2002038108A2 (en) * | 2000-11-03 | 2002-05-16 | The J. David Gladstone Institutes | Methods of treating disorders related to apoe |
-
2001
- 2001-12-21 WO PCT/US2001/049272 patent/WO2002053172A2/en not_active Application Discontinuation
- 2001-12-21 AU AU2002241664A patent/AU2002241664A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2131813A (en) * | 1982-12-16 | 1984-06-27 | Monsanto Co | Peptide substrates for mammalian collagenase |
EP0126009A1 (en) * | 1983-05-16 | 1984-11-21 | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | Peptide derivatives, their preparation and use as elastase inhibitors |
US5612194A (en) * | 1989-06-23 | 1997-03-18 | Trustees Of The University Of Pennsylvania | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors |
US5618790A (en) * | 1990-10-05 | 1997-04-08 | Queen's University At Kingston | Protease mediated drug delivery system |
US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
WO2000063233A2 (en) * | 1999-04-21 | 2000-10-26 | University Of Florida Research Foundation, Inc. | Peptides and the use thereof to control pests |
WO2001046220A2 (en) * | 1999-12-22 | 2001-06-28 | Polymun Scientific Immunbiologische Forschung Gmbh | Bioactive oligopeptides |
WO2002038108A2 (en) * | 2000-11-03 | 2002-05-16 | The J. David Gladstone Institutes | Methods of treating disorders related to apoe |
Also Published As
Publication number | Publication date |
---|---|
AU2002241664A1 (en) | 2002-07-16 |
WO2002053172A2 (en) | 2002-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003018748A3 (en) | Anti-cancer and wound healing compounds | |
EP0952215A3 (en) | Protease for activating clotting factor VII | |
ATE532858T1 (en) | HUMAN CLOTTING FACTOR VII POLYPEPTIDES | |
HUP9902698A2 (en) | Human bikunin | |
TR200101903T2 (en) | New malonic acid derivatives, their preparation processes. | |
WO1996035788A3 (en) | Kunitz type protease inhibitors | |
WO2003008443A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
WO2003066842A3 (en) | Method for producing recombinant proteins in micro-organisms | |
AU2003243097A1 (en) | Novel compounds | |
EP1118660A4 (en) | Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme | |
AU4166102A (en) | Multifunctional protease inhibitors and their use in treatment of disease | |
WO2002053172A3 (en) | Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover | |
WO1999063090A3 (en) | Protease inhibitor peptides | |
SPARATORE et al. | Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation | |
EP1497326A4 (en) | Prothrombin activating protein | |
YU76403A (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
WO2003053999A3 (en) | Selective arylguanidine peptides as urokinase inhibitors | |
WO2004106519A3 (en) | Mrp8/mrp14 inhibitors and the use thereof for preventing and/or treating hypertrophic scars and keloids | |
Dufour et al. | Limited proteolysis of β-lactoglobulin using thermolysin. Effects of calcium on the outcome of proteolysis | |
WO2003016273A3 (en) | Peptide arginals and methods for treating disseminated intravascular coagulation | |
ATE360438T1 (en) | USE OF INACTIVE CLN2 PROENZYME TO TREAT LINCL | |
WO2003036264A3 (en) | Treating diseases mediated by metalloprotease-shed proteins | |
Tschesche et al. | Function and structure of human leucocyte collagenase | |
WO2003033529A3 (en) | Tr4, tr4 activators, tr4 inhibitors or tr4-associated molecules for treating leukaemic diseases | |
LT2004079A (en) | Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |